{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:04Z","timestamp":1786982704307,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13760-024-02711-w","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T23:52:23Z","timestamp":1734997943000},"page":"395-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bromocriptine Versus Levodopa and other treatments in Parkinson\u2019s Disease: an updated Meta-analysis Involving more than 4000 patients across 12 randomized clinical trials"],"prefix":"10.1007","volume":"125","author":[{"given":"Maziar","family":"Afshar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Sane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"7","key":"2711_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s disease and parkinsonism. Am J Med 132(7):802\u2013807","journal-title":"Am J Med"},{"key":"2711_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2711_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","volume":"8","author":"AW Willis","year":"2022","unstructured":"Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R et al (2022) Incidence of Parkinson disease in North America. Npj Parkinson\u2019s Disease 8(1):170","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"10423","key":"2711_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C (2024) The epidemiology of Parkinson\u2019s disease. Lancet 403(10423):283\u2013292","journal-title":"Lancet"},{"issue":"5","key":"2711_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","volume":"19","author":"RM de Bie","year":"2020","unstructured":"de Bie RM, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of pharmacological therapy in Parkinson\u2019s disease: when, why, and how. Lancet Neurol 19(5):452\u2013461","journal-title":"Lancet Neurol"},{"issue":"24","key":"2711_CR6","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"PS Group","year":"2004","unstructured":"Group PS (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508","journal-title":"N Engl J Med"},{"issue":"6","key":"2711_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH et al (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84(6):797\u2013811","journal-title":"Ann Neurol"},{"key":"2711_CR8","unstructured":"Ozery M, Wadhwa R, Bromocriptine (2024) StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024. StatPearls Publishing LLC."},{"issue":"2","key":"2711_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0031-6997(25)06826-7","volume":"37","author":"AN Lieberman","year":"1985","unstructured":"Lieberman AN, Goldstein M (1985) Bromocriptine in Parkinson disease. Pharmacol Rev 37(2):217\u2013227","journal-title":"Pharmacol Rev"},{"issue":"6suppl6","key":"2711_CR10","first-page":"S11","volume":"50","author":"WC Koller","year":"1998","unstructured":"Koller WC, Rueda MG (1998) Mechanism of action of dopaminergic agents in Parkinson\u2019s disease. Neurology 50(6suppl6):S11\u2013S4","journal-title":"Neurology"},{"issue":"2","key":"2711_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/jnnp.39.2.184","volume":"39","author":"JD Parkes","year":"1976","unstructured":"Parkes JD, Marsden CD, Donaldson I, Galea-Debono A, Walters J, Kennedy G et al (1976) Bromocriptine treatment in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 39(2):184\u2013193","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2711_CR12","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","DOI":"10.1136\/bmj.n71"},{"key":"2711_CR13","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ343:d5928B1","DOI":"10.1136\/bmj.d5928"},{"key":"2711_CR14","unstructured":"GRADEpro GDT (2024) GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, Available from gradepro.org."},{"issue":"2","key":"2711_CR15","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Reviews 18(2):e1230","journal-title":"Campbell Syst Reviews"},{"issue":"6902","key":"2711_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","volume":"307","author":"Comparisons of therapeutic","year":"1993","unstructured":"Comparisons of therapeutic (1993) Effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson\u2019s disease: three year interim report. Parkinson\u2019s Disease Research Group in the United Kingdom. BMJ 307(6902):469\u2013472","journal-title":"BMJ"},{"issue":"8","key":"2711_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","volume":"57","author":"MA Hely","year":"1994","unstructured":"Hely MA, Morris J, Reid W, O\u2019Sullivan DJ, Williamson PM, Rail D et al (1994) The Sydney Multicentre Study of Parkinson\u2019s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57(8):903\u2013910","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2711_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.870100522","volume":"10","author":"A Bonnet","year":"1995","unstructured":"Bonnet A, Serre I, Marconi R, Agid Y, Dubois B (1995) A combined levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disorders: Official J Mov Disorder Soc 10(5):668\u2013671","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"5","key":"2711_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.410380512","volume":"38","author":"C Olanow","year":"1995","unstructured":"Olanow C, Hauser R, Gauguster L, Malapira T, Koller W, Hubble J et al (1995) The effect of deprenyl and levodopa on the progression of Parkinson\u2019s disease. Annals Neurology: Official J Am Neurol Association Child Neurol Soc 38(5):771\u2013777","journal-title":"Annals Neurology: Official J Am Neurol Association Child Neurol Soc"},{"issue":"3","key":"2711_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.47.3.785","volume":"47","author":"R Inzelberg","year":"1996","unstructured":"Inzelberg R, Nisipeanu P, Rabey J, Orlov E, Catz T, Kippervasser S et al (1996) Double-blind comparison of cabergoline and bromocriptine in Parkinson\u2019s disease patients with motor fluctuations. Neurology 47(3):785\u2013788","journal-title":"Neurology"},{"issue":"9","key":"2711_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/WNL.57.9.1687","volume":"57","author":"A Lees","year":"2001","unstructured":"Lees A, Katzenschlager R, Head J, Ben\u2013Shlomo Y (2001) Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57(9):1687\u20131694","journal-title":"Neurology"},{"key":"2711_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s007020200040","volume":"109","author":"E Brunt","year":"2002","unstructured":"Brunt E, Brooks D, Korczyn A, Montastruc J-L, Stocchi F, Group S (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson\u2019s disease not optimally controlled by L-dopa. J Neural Transm 109:489\u2013501","journal-title":"J Neural Transm"},{"issue":"10","key":"2711_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","volume":"18","author":"Y Mizuno","year":"2003","unstructured":"Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al (2003) Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson\u2019s disease. Mov Disord 18(10):1149\u20131156","journal-title":"Mov Disord"},{"key":"2711_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00415-003-0937-z","volume":"250","author":"J-H Im","year":"2003","unstructured":"Im J-H, Ha J-H, Cho I-S, Lee MC (2003) Ropinirole as an adjunct to levodopa in the treatment of Parkinson\u2019s disease: a 16-week bromocriptine controlled study. J Neurol 250:90\u201396","journal-title":"J Neurol"},{"issue":"4","key":"2711_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.20750","volume":"21","author":"A Castro-Caldas","year":"2006","unstructured":"Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P et al (2006) The Parkinson\u2013Control study: a 1\u2010year randomized, double\u2010blind trial comparing piribedil (150\u00a0mg\/day) with bromocriptine (25\u00a0mg\/day) in early combination with levodopa in Parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc 21(4):500\u2013509","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"7","key":"2711_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"R Katzenschlager","year":"2008","unstructured":"Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees A (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71(7):474\u2013480","journal-title":"Neurology"},{"issue":"4","key":"2711_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/mds.870080409","volume":"8","author":"MA Hely","year":"1993","unstructured":"Hely MA, Chey T, Wilson A, Williamson PM, O\u2019Sullivan DJ, Rail D et al (1993) Reliability of the Columbia scale for assessing signs of Parkinson\u2019s disease. Mov Disord 8(4):466\u2013472","journal-title":"Mov Disord"},{"issue":"1","key":"2711_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mds.870090112","volume":"9","author":"P Mart\u00ednez-Mart\u00edn","year":"1994","unstructured":"Mart\u00ednez-Mart\u00edn P, Gil-Nagel A, Gracia LM, G\u00f3mez JB, Mart\u00ednez-Sarri\u00e9s J, Bermejo F et al (1994) Unified Parkinson\u2019s disease rating scale characteristics and structure. Mov Disord 9(1):76\u201383","journal-title":"Mov Disord"},{"issue":"2","key":"2711_CR29","first-page":"257","volume":"5","author":"DD Webster","year":"1968","unstructured":"Webster DD (1968) Critical analysis of the disability in Parkinson\u2019s disease. Mod Treat 5(2):257\u2013282","journal-title":"Mod Treat"},{"issue":"5","key":"2711_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/mds.10248","volume":"17","author":"C Ramaker","year":"2002","unstructured":"Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc 17(5):867\u2013876","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"4","key":"2711_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mds.10011","volume":"17","author":"A Siderowf","year":"2002","unstructured":"Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I et al (2002) Test\u2013retest reliability of the Unified Parkinson\u2019s Disease Rating Scale in patients with early Parkinson\u2019s disease: results from a multicenter clinical trial. Mov Disord 17(4):758\u2013763","journal-title":"Mov Disord"},{"key":"2711_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00005053-196108000-00010","volume":"133","author":"GJ Canter","year":"1961","unstructured":"Canter GJ, De La Torre R, Mier M (1961) A method for evaluating disability in patients with Parkinson\u2019s disease. J Nerv Ment Dis 133:143\u2013147","journal-title":"J Nerv Ment Dis"},{"issue":"4 Suppl 1","key":"2711_CR33","first-page":"S2","volume":"47","author":"S Fahn","year":"2000","unstructured":"Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47(4 Suppl 1):S2\u20139 discussion S","journal-title":"Ann Neurol"},{"issue":"7","key":"2711_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VS et al (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28(7):863\u2013873","journal-title":"Mov Disord"},{"key":"2711_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.parkreldis.2018.09.005","volume":"60","author":"R Pahwa","year":"2019","unstructured":"Pahwa R, Isaacson SH, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R et al (2019) Impact of dyskinesia on activities of daily living in Parkinson\u2019s disease: results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism Relat Disord 60:118\u2013125","journal-title":"Parkinsonism Relat Disord"},{"key":"2711_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20 9","author":"M Hechtner","year":"2014","unstructured":"Hechtner M, Vogt T, Z\u00f6llner YF, Schr\u00f6der S, Sauer JB, Binder H et al (2014) Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20 9:969\u2013974","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"2711_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665\u2013677","journal-title":"Nat Rev Neurosci"},{"key":"2711_CR38","doi-asserted-by":"crossref","unstructured":"Goetz CG (2010) New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson\u2019s disease. Mov Disord. 25:104-109","DOI":"10.1002\/mds.22636"},{"key":"2711_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","volume":"29","author":"N Malek","year":"2014","unstructured":"Malek N, Grosset DG (2014) Medication adherence in patients with Parkinson\u2019s Disease. CNS Drugs 29:47\u201353","journal-title":"CNS Drugs"},{"issue":"1","key":"2711_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mds.26078","volume":"30","author":"W Poewe","year":"2015","unstructured":"Poewe W, Antonini A (2015) Novel formulations and modes of delivery of levodopa. Mov Disord 30(1):114\u2013120","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"2711_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2011.09.030","volume":"313","author":"MG Cersosimo","year":"2012","unstructured":"Cersosimo MG, Benarroch EE (2012) Autonomic involvement in Parkinson\u2019s disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 313(1\u20132):57\u201363","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"2711_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autneu.2011.02.004","volume":"161","author":"R Freeman","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 161(1\u20132):46\u201348","journal-title":"Auton Neurosci"},{"key":"2711_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10286-013-0219-5","volume":"24","author":"BH Shaw","year":"2014","unstructured":"Shaw BH, Claydon VE (2014) The relationship between orthostatic hypotension and falling in older adults. Clin Auton Res 24:3\u201313","journal-title":"Clin Auton Res"},{"key":"2711_CR44","unstructured":"Xiaoqin J (2011) The application of Pharmacoeconomics in Clinical Medicine decision making. China Modern Doctor"},{"key":"2711_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","volume":"22","author":"S Kalabina","year":"2018","unstructured":"Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B (2018) Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales. J Med Econ 22:215\u2013225","journal-title":"J Med Econ"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02711-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:51:36Z","timestamp":1745283096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02711-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02711-w","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and\/or falsification, double publication and\/or submission, redundancy, etc.) have been completely observed by the authors. This article extracted from medical student thesis with Ethical Code \u201cIR.MUK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}